These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27993663)

  • 41. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intermittent androgen suppression for rising PSA level after radiotherapy.
    Crook JM; O'Callaghan CJ; Duncan G; Dearnaley DP; Higano CS; Horwitz EM; Frymire E; Malone S; Chin J; Nabid A; Warde P; Corbett T; Angyalfi S; Goldenberg SL; Gospodarowicz MK; Saad F; Logue JP; Hall E; Schellhammer PF; Ding K; Klotz L
    N Engl J Med; 2012 Sep; 367(10):895-903. PubMed ID: 22931259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
    Wallander M; Axelsson KF; Lundh D; Lorentzon M
    Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
    Yu EY; Gulati R; Telesca D; Jiang P; Tam S; Russell KJ; Nelson PS; Etzioni RD; Higano CS
    J Clin Oncol; 2010 Jun; 28(16):2668-73. PubMed ID: 20421544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
    J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
    Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intermittent versus continuous androgen deprivation therapy.
    Higano CS
    J Natl Compr Canc Netw; 2014 May; 12(5):727-33. PubMed ID: 24812139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG; Canfield SE; Du XL
    Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
    Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
    Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intermittent androgen deprivation (IAD) for advanced prostate cancer. Why not the standard of therapy?].
    Prapotnich D; Sánchez-Salas R; Cathelineau X; Stakhovskyi O; Rocha JE; Vallancien G
    Arch Esp Urol; 2009 Nov; 62(9):689-94. PubMed ID: 19955592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and tolerability of intermittent androgen deprivation therapy: a literature review.
    Gruca D; Bacher P; Tunn U
    Int J Urol; 2012 Jul; 19(7):614-25. PubMed ID: 22435512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
    Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
    Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.